Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.

Quinney SK, Malireddy SR, Vuppalanchi R, Hamman MA, Chalasani N, Gorski JC, Hall SD.

Eur J Clin Pharmacol. 2013 Mar;69(3):439-48. doi: 10.1007/s00228-012-1339-x. Epub 2012 Jul 10.

2.

Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats.

Quinney SK, Galinsky RE, Jiyamapa-Serna VA, Chen Y, Hamman MA, Hall SD, Kimura RE.

Drug Metab Dispos. 2008 Jun;36(6):1097-101. doi: 10.1124/dmd.108.020644. Epub 2008 Mar 13.

PMID:
18339815
3.

Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects.

Jin Y, Wang YH, Miao J, Li L, Kovacs RJ, Marunde R, Hamman MA, Philips S, Hilligoss J, Hall SD.

Clin Pharmacol Ther. 2007 Nov;82(5):579-85. Epub 2007 Apr 18. Erratum in: Clin Pharmacol Ther. 2010 Jul;88(1):138. Phillips, S [corrected to Philips, S].

PMID:
17443134
4.

The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.

Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD.

Clin Pharmacol Ther. 2006 Mar;79(3):218-30. Epub 2006 Feb 7.

PMID:
16513446
5.

Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.

Borges S, Li L, Hamman MA, Jones DR, Hall SD, Gorski JC.

Drug Metab Dispos. 2005 Jul;33(7):1052-5. Epub 2005 Apr 8.

PMID:
15821042
6.

Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.

Pinto AG, Wang YH, Chalasani N, Skaar T, Kolwankar D, Gorski JC, Liangpunsakul S, Hamman MA, Arefayene M, Hall SD.

Clin Pharmacol Ther. 2005 Mar;77(3):178-88.

PMID:
15735612
7.

The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.

Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD.

Clin Pharmacol Ther. 2004 Jan;75(1):89-100.

PMID:
14749695
8.

The interaction between St John's wort and an oral contraceptive.

Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC.

Clin Pharmacol Ther. 2003 Dec;74(6):525-35.

PMID:
14663455
9.

The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.

Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, Hall SD.

Clin Pharmacol Ther. 2003 Sep;74(3):275-87. Erratum in: Clin Pharmacol Ther. 2004 Mar;75(3):249.

PMID:
12966371
10.

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA.

Drug Metab Dispos. 2002 Aug;30(8):883-91.

PMID:
12124305
11.

Effect of St John's wort on the pharmacokinetics of fexofenadine.

Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD.

Clin Pharmacol Ther. 2002 Jun;71(6):414-20.

PMID:
12087344
12.

The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.

Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD.

Clin Pharmacol Ther. 2001 Oct;70(4):317-26.

PMID:
11673747
13.

The effect of rifampin administration on the disposition of fexofenadine.

Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD.

Clin Pharmacol Ther. 2001 Mar;69(3):114-21.

PMID:
11240975
14.

Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes.

Hamman MA, Haehner-Daniels BD, Wrighton SA, Rettie AE, Hall SD.

Biochem Pharmacol. 2000 Jul 1;60(1):7-17.

PMID:
10807940
15.

Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily.

Gorski JC, Jones DR, Hamman MA, Wrighton SA, Hall SD.

Xenobiotica. 1999 Sep;29(9):931-44.

PMID:
10548453
16.

Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.

Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD.

J Pharmacol Exp Ther. 1999 Sep;290(3):1116-25.

PMID:
10454485
17.

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD.

Clin Pharmacol Ther. 1998 Aug;64(2):133-43.

PMID:
9728893
18.

Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C.

Hamman MA, Thompson GA, Hall SD.

Biochem Pharmacol. 1997 Jul 1;54(1):33-41.

PMID:
9296349
19.

Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity.

Jones DR, Gorski JC, Hamman MA, Hall SD.

J Chromatogr B Biomed Appl. 1996 Mar 29;678(1):105-11.

PMID:
8861660
20.

Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine.

Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, Swanson SP, Hamman MA, Wrighton SA.

J Pharmacol Exp Ther. 1996 Feb;276(2):658-66.

PMID:
8632334
21.

Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.

Hall SD, Hamman MA, Rettie AE, Wienkers LC, Trager WF, Vandenbranden M, Wrighton SA.

Drug Metab Dispos. 1994 Nov-Dec;22(6):975-8. No abstract available.

PMID:
7895619

Supplemental Content

Loading ...
Support Center